Unique ID issued by UMIN | UMIN000026041 |
---|---|
Receipt number | R000029926 |
Scientific Title | The safety and effect of embryo cryopreservation for fertility preservation |
Date of disclosure of the study information | 2017/02/09 |
Last modified on | 2020/08/18 08:30:45 |
The safety and effect of embryo cryopreservation for fertility preservation
The safety and effect of embryo cryopreservation for fertility preservation
The safety and effect of embryo cryopreservation for fertility preservation
The safety and effect of embryo cryopreservation for fertility preservation
Japan |
Cancer, Hematologic disease,Collagen disease,
Gastroenterology | Hepato-biliary-pancreatic medicine | Hematology and clinical oncology |
Clinical immunology | Surgery in general | Gastrointestinal surgery |
Hepato-biliary-pancreatic surgery | Endocrine surgery | Breast surgery |
Obstetrics and Gynecology | Pediatrics |
Malignancy
NO
In this study, we conduct embryo cryopreservation for fertility preservation and investigate the influence on primary disease, pregnancy rare of frozen embryo transfer, and safety in pregnancy.
Safety,Efficacy
The recurrence of primary disease, Newborn anomalies and malformations
Oocytes retrieved, Fertilization rate, Ovarian reserve after treatment of primary disease
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Patients undergo stimulation and in vitro fertilization(IVF) for fertility preservation before or in the course of treatment for primary disease.
Combined therapy: one FSH/hMG injection(150-450 IU)per day with GnRH agonist or GnRH antagonist until maturation of follicles, one hCG injection (5000-15000 IU)per day when follicles mature.
18 | years-old | <= |
45 | years-old | >= |
Female
1)Cancer, hematological disease, or collagen disease patients.
2)The physicians of primary disease make a written request for fertility preservation.
3)The patients who are expected long-term survival.
4)The patients who have the ability to provide written informed consent.
1)The patients who are not expected long-term survival.
2)The patients who have the previous history of gynecologic malignant diseases (ovarian cancer, cervical adenocarcinoma)
3)The patients who are during the period of pregnancy or the possibility of pregnancy.
4)The patients judged to be inappropriate for the study by the physicians.
50
1st name | Nao |
Middle name | |
Last name | Suzuki |
St. Marianna University of Medicine
Department of Obstetrics and Gynecology
2168511
2-16-1, Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511 Japan
044-977-8111
nao@marianna-u.ac.jp
1st name | Nao |
Middle name | |
Last name | Suzuki |
St. Marianna University of Medicine
Department of Obstetrics and Gynecology
2168511
2-16-1, Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511 Japan
044-977-8111
nao@marianna-u.ac.jp
St. Marianna University of Medicine
St. Marianna University of Medicine
Other
IRB of St. Marianna University
2-16-1 Sugao, Miyamae-ku, Kawasaki Kanagawa JAPAN.
044-977-8111
k-sienbu.mail@marianna-u.ac.jp
NO
2017 | Year | 02 | Month | 09 | Day |
Unpublished
Totally 30 contributors received oocyte pick up before cancer treatment as fertility preservation. Until now, they don't have any side effect. We will follo up them to assess the ling term efficathy and safety.
Enrolling by invitation
2017 | Year | 01 | Month | 26 | Day |
2017 | Year | 01 | Month | 26 | Day |
2017 | Year | 02 | Month | 09 | Day |
2040 | Year | 03 | Month | 31 | Day |
2017 | Year | 02 | Month | 07 | Day |
2020 | Year | 08 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029926
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |